IFRX compared with VTGN: revenue, margins and what each company keeps, and the suppliers and customers both name

IFRXInflaRx N.V.

Mkt capRevenueRevenue

VTGNVistagen Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

IFRXInflaRx N.V.

VTGNVistagen Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

IFRXInflaRx N.V.

1.47▼−9.30%· post 1.74

Mkt cap$107.0MRevenue—Revenue—

VTGNVistagen Therapeutics, Inc.

0.19▲+11.49%· post 0.18

ClosedNov 4 '26

Mkt cap$7.5MRevenue$1MQ1 FY27Revenue$1MFY26

Compare

ClosedNov 4 '26

IFRXInflaRx N.V.

VTGNVistagen Therapeutics, Inc.

1.47▼−9.30%post 1.74

Price

0.19▲+11.49%post 0.18

$107.0M

Mkt cap

$7.5M

—

Revenue

$1MQ1 FY27

—

Revenue

$1MFY26

IFRX1.47▼−9.30%vsVTGN0.19▲+11.49%ClosedNov 4 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

IFRX: latest quarter not drawable. VTGN: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only IFRX 0

None

Shared 0

No disclosed counterparties: IFRX.

Only VTGN 4

—Pherin Pharmaceuticals, Inc. (Pherin)unlistedsupplier

—AffaMedunlistedcustomer

—AffaMed Therapeuticsunlistedcustomer

—Fuji Pharmaunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

IFRX, solidVTGN, dashed